Apyx Price To Sales Ratio vs Capex To Depreciation Analysis

APYX Stock

USD 2.95 0.15 4.84%

Apyx Medical financial indicator trend analysis is way more than just evaluating Apyx Medical prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Apyx Medical is a good investment. Please check the relationship between Apyx Medical Price To Sales Ratio and its Capex To Depreciation accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Apyx Medical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in private.

For more information on how to buy Apyx Stock please use our How to Invest in Apyx Medical guide.

Price To Sales Ratio vs Capex To Depreciation

Price To Sales Ratio vs Capex To Depreciation Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Apyx Medical Price To Sales Ratio account and Capex To Depreciation. At this time, the significance of the direction appears to have no relationship.

The correlation between Apyx Medical's Price To Sales Ratio and Capex To Depreciation is 0.06. Overlapping area represents the amount of variation of Price To Sales Ratio that can explain the historical movement of Capex To Depreciation in the same time period over historical financial statements of Apyx Medical, assuming nothing else is changed. The correlation between historical values of Apyx Medical's Price To Sales Ratio and Capex To Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Price To Sales Ratio of Apyx Medical are associated (or correlated) with its Capex To Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Depreciation has no effect on the direction of Price To Sales Ratio i.e., Apyx Medical's Price To Sales Ratio and Capex To Depreciation go up and down completely randomly.

Correlation Coefficient

0.06

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Apyx Medical stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Apyx Medical sales, a figure that is much harder to manipulate than other Apyx Medical multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Capex To Depreciation

The ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets.

Most indicators from Apyx Medical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Apyx Medical current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Apyx Medical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in private.

For more information on how to buy Apyx Stock please use our How to Invest in Apyx Medical guide.At this time, Apyx Medical's Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 264.6 K in 2025, whereas Sales General And Administrative To Revenue is likely to drop 0.58 in 2025.

	2022	2023	2024	2025 (projected)
Interest Expense	15K	2.5M	5.9M	6.2M
Depreciation And Amortization	890K	692K	599K	724.3K

Interest Expense Depreciation And Amortization

Apyx Medical fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt
Total Assets		0.09	0.51	0.74	0.83	0.44	0.17	-0.61	0.21	0.65	0.75	-0.09	0.24	0.91	0.57	-0.31	0.04	0.83	0.1	0.19	0.77	0.59	0.27	0.52	0.95	0.79
Short Long Term Debt Total	0.09		0.44	0.37	-0.36	0.02	-0.39	0.49	-0.83	0.29	0.35	0.08	0.76	0.14	0.33	-0.22	-0.17	0.11	1.0	0.22	-0.09	0.64	0.97	0.49	0.25	0.41
Other Current Liab	0.51	0.44		0.77	0.25	0.08	-0.26	0.04	-0.48	0.63	0.4	-0.27	0.61	0.42	0.83	-0.24	0.19	0.64	0.47	0.27	0.4	0.82	0.6	0.35	0.61	0.8
Total Current Liabilities	0.74	0.37	0.77		0.49	0.28	-0.13	-0.42	-0.32	0.86	0.81	-0.23	0.57	0.64	0.9	-0.31	0.2	0.77	0.39	0.25	0.64	0.85	0.58	0.45	0.82	0.88
Total Stockholder Equity	0.83	-0.36	0.25	0.49		0.32	0.35	-0.77	0.6	0.29	0.54	-0.13	-0.13	0.83	0.36	-0.33	0.05	0.64	-0.35	-0.04	0.73	0.29	-0.19	0.1	0.8	0.47
Property Plant And Equipment Net	0.44	0.02	0.08	0.28	0.32		0.2	-0.32	0.01	0.4	0.32	0.76	0.29	0.16	0.29	-0.73	-0.73	0.6	0.03	0.71	0.35	0.32	0.09	0.79	0.29	0.24
Current Deferred Revenue	0.17	-0.39	-0.26	-0.13	0.35	0.2		-0.43	0.42	-0.1	0.06	-0.09	-0.69	0.26	-0.34	-0.21	-0.1	0.27	-0.39	-0.3	0.32	-0.13	-0.37	-0.08	0.1	-0.11
Net Debt	-0.61	0.49	0.04	-0.42	-0.77	-0.32	-0.43		-0.58	-0.33	-0.63	0.14	0.27	-0.54	-0.29	0.13	-0.16	-0.48	0.48	0.21	-0.57	-0.04	0.32	-0.04	-0.52	-0.35
Retained Earnings	0.21	-0.83	-0.48	-0.32	0.6	0.01	0.42	-0.58		-0.35	-0.12	-0.05	-0.71	0.25	-0.4	0.12	0.06	-0.09	-0.84	-0.31	0.2	-0.6	-0.82	-0.38	0.06	-0.29
Accounts Payable	0.65	0.29	0.63	0.86	0.29	0.4	-0.1	-0.33	-0.35		0.62	-0.12	0.47	0.41	0.74	-0.14	0.16	0.76	0.31	0.45	0.55	0.68	0.48	0.62	0.6	0.76
Cash	0.75	0.35	0.4	0.81	0.54	0.32	0.06	-0.63	-0.12	0.62		-0.12	0.41	0.73	0.65	-0.3	0.09	0.65	0.36	-0.02	0.58	0.66	0.51	0.46	0.81	0.78
Non Current Assets Total	-0.09	0.08	-0.27	-0.23	-0.13	0.76	-0.09	0.14	-0.05	-0.12	-0.12		0.27	-0.28	-0.12	-0.62	-0.91	0.02	0.08	0.67	-0.18	-0.04	0.01	0.54	-0.2	-0.28
Non Currrent Assets Other	0.24	0.76	0.61	0.57	-0.13	0.29	-0.69	0.27	-0.71	0.47	0.41	0.27		0.1	0.7	-0.34	-0.23	0.29	0.77	0.53	0.02	0.71	0.81	0.61	0.34	0.57
Cash And Short Term Investments	0.91	0.14	0.42	0.64	0.83	0.16	0.26	-0.54	0.25	0.41	0.73	-0.28	0.1		0.41	-0.27	0.12	0.65	0.15	-0.12	0.71	0.54	0.28	0.25	0.95	0.68
Net Receivables	0.57	0.33	0.83	0.9	0.36	0.29	-0.34	-0.29	-0.4	0.74	0.65	-0.12	0.7	0.41		-0.31	0.12	0.67	0.36	0.29	0.45	0.82	0.53	0.42	0.66	0.85
Good Will	-0.31	-0.22	-0.24	-0.31	-0.33	-0.73	-0.21	0.13	0.12	-0.14	-0.3	-0.62	-0.34	-0.27	-0.31		0.77	-0.47	-0.22	-0.49	-0.3	-0.49	-0.27	-0.46	-0.37	-0.16
Common Stock Total Equity	0.04	-0.17	0.19	0.2	0.05	-0.73	-0.1	-0.16	0.06	0.16	0.09	-0.91	-0.23	0.12	0.12	0.77		-0.06	-0.16	-0.52	0.15	-0.06	-0.1	-0.49	0.08	0.23
Common Stock Shares Outstanding	0.83	0.11	0.64	0.77	0.64	0.6	0.27	-0.48	-0.09	0.76	0.65	0.02	0.29	0.65	0.67	-0.47	-0.06		0.13	0.39	0.77	0.75	0.3	0.65	0.78	0.77
Non Current Liabilities Total	0.1	1.0	0.47	0.39	-0.35	0.03	-0.39	0.48	-0.84	0.31	0.36	0.08	0.77	0.15	0.36	-0.22	-0.16	0.13		0.23	-0.08	0.66	0.97	0.5	0.26	0.43
Inventory	0.19	0.22	0.27	0.25	-0.04	0.71	-0.3	0.21	-0.31	0.45	-0.02	0.67	0.53	-0.12	0.29	-0.49	-0.52	0.39	0.23		0.17	0.34	0.26	0.71	0.08	0.14
Other Current Assets	0.77	-0.09	0.4	0.64	0.73	0.35	0.32	-0.57	0.2	0.55	0.58	-0.18	0.02	0.71	0.45	-0.3	0.15	0.77	-0.08	0.17		0.46	0.09	0.31	0.74	0.59
Other Stockholder Equity	0.59	0.64	0.82	0.85	0.29	0.32	-0.13	-0.04	-0.6	0.68	0.66	-0.04	0.71	0.54	0.82	-0.49	-0.06	0.75	0.66	0.34	0.46		0.79	0.57	0.73	0.81
Total Liab	0.27	0.97	0.6	0.58	-0.19	0.09	-0.37	0.32	-0.82	0.48	0.51	0.01	0.81	0.28	0.53	-0.27	-0.1	0.3	0.97	0.26	0.09	0.79		0.55	0.43	0.59
Property Plant And Equipment Gross	0.52	0.49	0.35	0.45	0.1	0.79	-0.08	-0.04	-0.38	0.62	0.46	0.54	0.61	0.25	0.42	-0.46	-0.49	0.65	0.5	0.71	0.31	0.57	0.55		0.4	0.53
Total Current Assets	0.95	0.25	0.61	0.82	0.8	0.29	0.1	-0.52	0.06	0.6	0.81	-0.2	0.34	0.95	0.66	-0.37	0.08	0.78	0.26	0.08	0.74	0.73	0.43	0.4		0.83
Short Term Debt	0.79	0.41	0.8	0.88	0.47	0.24	-0.11	-0.35	-0.29	0.76	0.78	-0.28	0.57	0.68	0.85	-0.16	0.23	0.77	0.43	0.14	0.59	0.81	0.59	0.53	0.83

Click cells to compare fundamentals

Apyx Medical Account Relationship Matchups

Apyx Medical fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	74.1M	68.7M	51.8M	79.2M	64.8M	34.2M
Short Long Term Debt Total	676K	305K	796K	38.5M	38.8M	40.7M
Other Current Liab	6.3M	9.0M	7.6M	8.8M	7.4M	7.8M
Total Current Liabilities	9.2M	13.2M	11.9M	12.7M	10.7M	11.3M
Total Stockholder Equity	63.7M	53.7M	37.6M	26.7M	14.2M	24.1M
Property Plant And Equipment Net	7.2M	6.9M	7.6M	7.1M	6.7M	5.4M
Current Deferred Revenue	5.6M	533K	853K	488K	439.2K	417.2K
Net Debt	(41.2M)	(30.6M)	(9.4M)	(5.2M)	7.0M	7.4M
Retained Earnings	2.6M	(12.6M)	(35.7M)	(54.4M)	(77.9M)	(74.0M)
Accounts Payable	1.5M	2.6M	2.7M	2.7M	2.6M	1.3M
Cash	41.9M	30.9M	10.2M	43.7M	31.7M	33.3M
Non Current Assets Total	8.0M	8.0M	8.8M	8.9M	8.4M	8.3M
Non Currrent Assets Other	807K	1.1M	1.2M	1.7M	1.7M	1.7M
Cash And Short Term Investments	41.9M	30.9M	10.2M	43.7M	31.7M	33.3M
Net Receivables	17.3M	21.2M	18.2M	14.1M	15.5M	16.3M
Common Stock Shares Outstanding	34.2M	34.3M	34.5M	34.6M	35.5M	22.9M
Liabilities And Stockholders Equity	74.1M	68.7M	51.8M	79.2M	64.8M	34.2M
Non Current Liabilities Total	1.1M	1.5M	2.1M	39.6M	39.8M	41.8M
Inventory	4.1M	6.8M	11.8M	9.9M	7.6M	5.4M
Other Current Assets	2.8M	1.9M	2.7M	2.7M	1.7M	1.4M
Other Stockholder Equity	61.1M	66.2M	73.3M	81.1M	92.1M	96.7M
Total Liab	10.3M	14.7M	14.0M	52.3M	50.5M	53.0M
Property Plant And Equipment Gross	7.2M	6.9M	7.6M	10.7M	10.7M	5.6M
Total Current Assets	66.1M	60.7M	43.0M	70.4M	56.4M	59.3M
Short Term Debt	728K	574K	506K	734K	710K	455.6K
Other Assets	191K	1.5M	1.1M	1.2M	1.4M	1.1M
Property Plant Equipment	6.6M	7.2M	6.6M	6.8M	7.8M	5.8M
Net Tangible Assets	71.3M	63.7M	53.7M	37.6M	43.2M	40.5M
Retained Earnings Total Equity	14.5M	2.6M	(12.6M)	(35.7M)	(41.1M)	(39.0M)
Capital Surpluse	56.7M	61.1M	66.2M	73.3M	84.3M	51.5M
Non Current Liabilities Other	166K	184K	724K	198K	259K	356.3K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

VOO	Vanguard SP 500
XLK	Technology Select Sector
XLV	Health Care Select

Additional Tools for Apyx Stock Analysis

When running Apyx Medical's price analysis, check to measure Apyx Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apyx Medical is operating at the current time. Most of Apyx Medical's value examination focuses on studying past and present price action to predict the probability of Apyx Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apyx Medical's price. Additionally, you may evaluate how the addition of Apyx Medical to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

Apyx Price To Sales Ratio vs Capex To Depreciation Analysis

Price To Sales Ratio vs Capex To Depreciation

Price To Sales Ratio vs Capex To Depreciation Correlation Analysis

Correlation Coefficient

Price To Sales Ratio

Capex To Depreciation

Apyx Medical fundamental ratios Correlations

Apyx Medical Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Apyx Medical fundamental ratios Accounts

Also Currently Popular

Additional Tools for Apyx Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Liabilities Total	+ 1.0	Short Long Term Debt Total
Total Liab	+ 0.97	Short Long Term Debt Total
Total Liab	+ 0.97	Non Current Liabilities Total
Total Current Assets	+ 0.95	Total Assets
Total Current Assets	+ 0.95	Cash And Short Term Investments
Cash And Short Term Investments	+ 0.91	Total Assets

Common Stock Total Equity	- 0.91	Non Current Assets Total
Non Current Liabilities Total	- 0.84	Retained Earnings
Retained Earnings	- 0.83	Short Long Term Debt Total
Total Liab	- 0.82	Retained Earnings
Net Debt	- 0.77	Total Stockholder Equity
Common Stock Total Equity	- 0.73	Property Plant And Equipment Net